GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » EBIT

Ionis Pharmaceuticals (Ionis Pharmaceuticals) EBIT

: $-258.4 Mil (TTM As of Dec. 2023)
View and export this data going back to 1991. Start your Free Trial

Ionis Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $18.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-258.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ionis Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -13.44%. Ionis Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 29.63%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ionis Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -5.06%.


Ionis Pharmaceuticals EBIT Historical Data

The historical data trend for Ionis Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 351.21 -128.35 -24.75 -255.19 -258.37

Ionis Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.93 -97.12 -58.89 -120.43 18.08

Competitive Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's EV-to-EBIT falls into.



Ionis Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-258.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ionis Pharmaceuticals  (NAS:IONS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ionis Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-24.448 * ( 1 - -234.77% )/( (597.878 + 620.237)/ 2 )
=-81.8445696/609.0575
=-13.44 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2933.971 - 155.653 - ( 2235.582 - max(0, 404.21 - 2584.65+2235.582))
=597.878

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2990.072 - 176.072 - ( 2331.201 - max(0, 448.09 - 2641.853+2331.201))
=620.237

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Ionis Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=72.328/( ( (245.238 + max(-197.501, 0)) + (242.939 + max(-182.053, 0)) )/ 2 )
=72.328/( ( 245.238 + 242.939 )/ 2 )
=72.328/244.0885
=29.63 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 25.634 + 181.075) - (155.653 + 204.824 + 43.733)
=-197.501

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 28.425 + 184.449) - (176.072 + 151.128 + 67.727)
=-182.053

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ionis Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-258.36/5108.364
=-5.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ionis Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Executives
Brian Birchler officer: EVP, Corp and Development Ops C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Patrick R. O'neil officer: SVP, Legal and General Counsel C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Onaiza Cadoret-manier officer: Chief Corp Dev and Cml Officer 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eugene Schneider officer: EVP, Chf Clinical Develop Offc C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Joseph Baroldi officer: Chief Business Officer C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eric Swayze officer: SVP, Research 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Brett P Monia director, officer: Senior Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Richard S Geary officer: Senior Vice President 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Elizabeth L Hougen officer: SVP, Finance and CFO 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett officer: Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
B Lynne Parshall director, officer: Executive Vice President, CFO 2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Spencer R Berthelsen director 2855 GAZELLE COURT, CARLSBAD CA 92010
Frederick T Muto director 2855 GAZELLE COURT, CARLSBAD CA 92010